Whole organism blood stage vaccines against malaria

Vaccine

Volumn 33, Issue 52, 2015, Pages 7469-7475

  Stanisic, Danielle I ^a   Good, Michael F ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Blood stage; Malaria; Plasmodium; Vaccine; Whole parasite

Indexed keywords

ASPARTIC PROTEINASE; LIVE VACCINE; MALARIA VACCINE; NUCLEOSIDE TRANSPORTER; PARASITE ANTIGEN;

ARTICLE; BLOOD; BLOOD STAGE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROL STRATEGY; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG SAFETY; DRUG STORAGE; EVIDENCE BASED PRACTICE; GENE INACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; LIFE CYCLE STAGE; MALARIA; NONHUMAN; PARASITE VIRULENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RADIATION ATTENUATION; VACCINATION; VACCINE PRODUCTION; VECTOR CONTROL; ANIMAL; IMMUNOLOGY; MOUSE; PHYSIOLOGY; SPOROZOITE;

ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; MICE; SPOROZOITES; VACCINATION; VACCINES, ATTENUATED;

EID: 84951128603     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.057     Document Type: Article

References (47)

1. World Health Organisation World Malaria Report 2013 2013, World Health Organisation.
2. Sagara I., Dicko A., Ellis R.D., Fay M.P., Diawara S.I., Assadou M.H., et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009, 27:3090-3098.
3. Ogutu B.R., Apollo O.J., McKinney D., Okoth W., Siangla J., Dubovsky F., et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 2009, 4:e4708.
4. Sirima S.B., Cousens S., Druilhe P. Protection against malaria by MSP3 candidate vaccine. N Engl J Med 2011, 365:1062-1064.
5. Olotu A., Fegan G., Wambua J., Nyangweso G., Awuondo K.O., Leach A., et al. Four-year efficacy of RTS S/AS01E and its interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120.
6. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
7. Zepp F. Principles of vaccine design - lessons from nature. Vaccine 2010, 28(Suppl. 3):C14-C24.
8. Thomson K.J., Freund J., Sommer H.E., Walter A.W. Immunization of ducks against malaria by means of killed parasites with or without adjuvants. Am J Trop Med Hyg 1947, 27:79-105.
9. Freund J., Thomson K.J., Sommer H.E., Walter A.W., Pisani T.M. Immunization of monkeys against malaria by means of killed parasites with adjuvants. Am J Trop Med Hyg 1948, 28:1-22.
10. Siddiqui W.A. An effective immunization of experimental monkeys against a human malaria parasite, Plasmodium falciparum. Science 1977, 197:388-389.
11. McCarthy J.S., Good M.F. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin 2010, 6:114-123.
12. Trager W., Jensen J. Human malaria parasites in continuous culture. Science 1976, 193.
13. Kemp D.J., Coppel R.L., Cowman A.F., Saint R.B., Brown G.V., Anders R.F. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc Natl Acad Sci U S A 1983, 80:3787-3791.
14. Ellis J., Ozaki L.S., Gwadz R.W., Cochrane A.H., Nussenzweig V., Nussenzweig R.S., et al. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 1983, 302:536-538.
15. Collins W.E., Jeffery G.M. A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg 1999, 61:20-35.
16. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
17. Edstein M.D., Kotecka B.M., Anderson K.L., Pombo D.J., Kyle D.E., Rieckmann K.H., et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother 2005, 49:4421-4422.
18. Elliott S.R., Kuns R.D., Good M.F. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun 2005, 73:2478-2485.
19. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A 2013, 110:7862-7867.
20. Pinzon-Charry A., McPhun V., Kienzle V., Hirunpetcharat C., Engwerda C., McCarthy J., et al. Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J Clin Invest 2010, 120:2967-2978.
21. Xu H., Wipasa J., Yan H., Zeng M., Makobongo M.O., Finkelman F.D., et al. The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J Exp Med 2002, 195:881-892.
22. Mata E., Salvador A., Igartua M., Hernandez R.M., Pedraz J.L. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int 2013, 2013:282913.
23. Gerald N.J., Majam V., Mahajan B., Kozakai Y., Kumar S. Protection from experimental cerebral malaria with a single dose of radiation-attenuated, blood-stage Plasmodium berghei parasites. PLoS ONE 2011, 6:e24398.
24. Miyagami T., Igarshi I., Suzuki M. Plasmodium berghei: long lasting immunity induced by a permanent attenuated mutant. Zentralbl Bakteriol Mikrobiol Hyg A 1987, 264:502-512.
25. Waki S., Yonome I., Suzuki M. Plasmodium falciparum: attenuation by irradiation. Exp Parasitol 1983, 56:339-345.
26. Oakley M.S., Gerald N., Anantharaman V., Gao Y., Majam V., Mahajan B., et al. Radiation-induced cellular and molecular alterations in asexual intraerythrocytic Plasmodium falciparum. J Infect Dis 2013, 207:164-174.
27. Yanow S.K., Purcell L.A., Pradel G., Sato A., Rodriguez A., Lee M., et al. Potent antimalarial and transmission-blocking activities of centanamycin, a novel DNA-binding agent. J Infect Dis 2008, 197:527-534.
28. Purcell L.A., Yanow S.K., Lee M., Spithill T.W., Rodriguez A. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun 2008, 76:1193-1199.
29. Good M.F., Reiman J.M., Rodriguez I.B., Ito K., Yanow S.K., El-Deeb I.M., et al. Cross-species malaria immunity induced by chemically attenuated parasites. J Clin Invest 2013, 123:3353-3362.
30. Dahl E.L., Shock J.L., Shenai B.R., Gut J., DeRisi J.L., Rosenthal P.J. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2006, 50:3124-3130.
31. Yeh E., DeRisi J.L. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol 2011, 9:e1001138.
32. Balu B., Singh N., Maher S.P., Adams J.H. A genetic screen for attenuated growth identifies genes crucial for intraerythrocytic development of Plasmodium falciparum. PLoS ONE 2010, 5:e13282.
33. Ting L.M., Gissot M., Coppi A., Sinnis P., Kim K. Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat Med 2008, 14:954-958.
34. Aly A.S., Downie M.J., Mamoun C.B., Kappe S.H. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell Microbiol 2010, 12:930-938.
35. Bonilla J.A., Moura P.A., Bonilla T.D., Yowell C.A., Fidock D.A., Dame J.B. Effects on growth, hemoglobin metabolism and paralogous gene expression resulting from disruption of genes encoding the digestive vacuole plasmepsins of Plasmodium falciparum. Int J Parasitol 2007, 37:317-327.
36. Spaccapelo R., Janse C.J., Caterbi S., Franke-Fayard B., Bonilla J.A., Syphard L.M., et al. Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria. Am J Pathol 2010, 176:205-217.
37. Spaccapelo R., Aime E., Caterbi S., Arcidiacono P., Capuccini B., Di Cristina M., et al. Disruption of plasmepsin-4 and merozoites surface protein-7 genes in Plasmodium berghei induces combined virulence-attenuated phenotype. Sci Rep 2011, 1:39.
38. Chan J.A., Fowkes F.J., Beeson J.G. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell Mol Life Sci 2014, 71:3633-3657.
39. D'Ombrain M., Voss T., Maier A., Hansen D., Cowman A., Schofield L. Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon gamma. Cell Host Microbe 2007, 2:130-138.
40. Elliott S.R., Spurck T.P., Dodin J.M., Maier A.G., Voss T.S., Yosaatmadja F., et al. Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1. Infect Immun 2007, 75:3621-3632.
41. Rug M., Prescott S.W., Fernandez K.M., Cooke B.M., Cowman A.F. The role of KAHRP domains in knob formation and cytoadherence of P. falciparum-infected human erythrocytes. Blood 2006, 108:370-378.
42. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 31:4975-4983.
43. Stanisic D.I., Liu X.Q., De S.L., BatzloffM.R., Forbes T., Davis C.B., et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J 2015, 14:143.
44. O'Neill M.T., Phuong T., Healer J., Richard D., Cowman A.F. Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied site-specific recombination. Int J Parasitol 2011, 41:117-123.
45. van Schaijk B.C., Vos M.W., Janse C.J., Sauerwein R.W., Khan S.M. Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase. PLoS ONE 2010, 5:e15121.
46. Mordmuller B., Supan C., Sim K.L., Gomez-Perez G.P., Ospina Salazar C.L., Held J., et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 2015, 14:117.
47. Garcia C.R., Manzi F., Tediosi F., Hoffman S.L., James E.R. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine 2013, 31:380-386.